Showing results (91-100 of 109) with videos related to
Sort By:
Pageof 11
Molecular Cancer Therapeutics|July 23, 2013
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900Elizabeth Blackwood, Jennifer Epler, Ivana Yen, et al.Health Technology Assessment (Winchester, England)|March 9, 2018
The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluationMatthew Cox, Catherine O'Connor, Katie Biggs, et al.Neuro-Oncology|February 23, 2011
DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expressionShichun Zheng, E Andres Houseman, Zachary Morrison, et al.Cell|February 21, 2017
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in CancerMichael R Burgess, Eugene Hwang, Rana Mroue, et al.Bioorganic & Medicinal Chemistry Letters|June 14, 2017
Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistanceTerry D Crawford, Steffan Vartanian, Alexandre Côté, et al.Cancer Research|September 18, 2025
Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung CancerMelat T Gebru, Timothy E Hoffman, Aaron Boudreau, et al.Proceedings of the National Academy of Sciences of the United States of America|November 9, 2012
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancersChaitali Parikh, Vasantharajan Janakiraman, Wen-I Wu, et al.Nature Chemical Biology|July 30, 2013
Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell deathPaola Magnaghi, Roberto D'Alessio, Barbara Valsasina, et al.The New England Journal of Medicine|November 12, 2005
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitorsIngo K Mellinghoff, Maria Y Wang, Igor Vivanco, et al.Journal of Medicinal Chemistry|December 19, 2012
Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationshipsPaolo Polucci, Paola Magnaghi, Mauro Angiolini, et al.Pageof 11